logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    
Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases. In this interview with The Life Sciences Report, Moussatos describes a group of biotech stocks rich with upcoming catalysts,…
Read more...
Shares of Small-Cap Star Arrowhead Research Corp. (ARWR) are up sharply on Tuesday, with gains in excess of 15% in early trading. The move comes without any clear news item motivating the gains and could be connected to momentum trading related to a breakout from a double-top pattern with resistance…
Read more...
Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report, William Plovanic of Canaccord Genuity highlights investment opportunities…
Read more...
For former drug researcher Raghuram "Ram" Selvaraju, picking biotech stocks is both science and art. It's about understanding the competitive landscape and the mechanisms of drug action, and then making sure all the pieces fit together for a plausible investment case. In this interview with The Life Sciences Report, the…
Read more...
Medical technology is intimately linked to regenerative medicine. You could say these industries have a thunder-and-lightning relationship—you can't have one without the other. Mark Landy, director of research for medical technology and regenerative medicine at Summer Street Research Partners, has staked out the intertwined sectors as his universe of coverage.…
Read more...
In the U.S. alone, some 3.2 million people have chronic hepatitis C virus. Between 75% and 85% of people infected with hepatitis C virus develop chronic infection. According to data summarized in an issue of Annals of Internal Medicine, more U.S. residents are now dying of hepatitis C complications than…
Read more...
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies…
Read more...
Small-Cap Star BioCryst Pharmaceuticals (BCRX) was climbing again on Monday, with shares spiking 5.42%. Shares have been having a rocky year, climbing sharply at the start of the year, then getting caught in the risk-off swoon that hit small-caps and biotechs especially hard in early March. However, the company rebounded…
Read more...
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends when looking at portfolio options in the healthcare sector. A medical researcher turned…
Read more...
Gilead Sciences Inc. (GILD) posted Q2 2014 earnings of $2.36 a share, easily beating the consensus estimate by 58 cents.Sales came in at $6.53 billion, topping earlier estimate by 12%. More than half of the company’s revenue is generated by its cash cow, Hep C drug Sovaldi. The fruitful earnings…
Read more...
Innocoll GmbH ($INNL) is a global, commercial stage, specialty pharmaceutical company, with late stage development programs targeting areas of significant unmet medical need. It is headquartered in Athlone, Ireland, Ten other companies are scheduled for the week of July 21, 2014. The full IPO calendar is available at IPOpremium. The…
Read more...
Ocular Therapeutix ($OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. It is headquartered in Bedford, MA, Ten other companies are scheduled for the week of July 21, 2014.  The full IPO…
Read more...
Page 1 of 44

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.